

**IMMUNOLOGICAL STUDIES OF DNA (pJWVacII) AND  
SURFACE DISPLAY (r-STVacII) VACCINE CANDIDATES  
EXPRESSING A SYNTHETIC MULTIEPITOPE GENE OF  
*MYCOBACTERIUM TUBERCULOSIS* IN A PRIME BOOST  
STRATEGY USING A MOUSE MODEL**

by

**NORHANANI BT. MOHD REDZWAN**

**Thesis submitted in fulfillment of the  
requirement for the Degree of  
Master of Science**

**2008**

## ACKNOWLEDGEMENTS

In the name of Allah, the most Generous and the most Merciful. All praise is due to Allah, for giving me inspiration and stoutheartedness along this journey.

During this research project, there are several people involved directly or indirectly whom I wish to acknowledge in this section.

I wish to thank my supervisor, Assoc. Prof. Mustaffa Musa, for his support, excellent guidance and supervision throughout the experimental work, research investigations and also for providing all the necessary facilities to carry out this study. His guidance is greatly appreciated.

I would like also to thank my Co-supervisor, Prof. Zainul F. Zainuddin for his kind guidance, overall comments and helpful discussions during this study. Thanks also to Mr. Jamaruddin Mat Asan from PPSK and Mrs. Melisa from the Immunology Laboratory for technical assistance in doing some experimental work.

Special thanks to my friends and colleagues in the laboratory especially Azura, Ayuni, Tini, Bad, Eza, Nurul, Abdah and Kak Salwana. In addition, I would like to thank my friends in the NMN and SS research groups for both friendship and assistance during the course of this study.

Not to forget, Dr. Nurul Khaiza, Dr. Noor Suryani, Dr. Che Maraina, Dr. Wan Zuraida and all staff in Immunology department for their support. To all my friends outside the laboratory, thanks for being there and encouraging me when needed. I hope you feel my gratitude.

My deepest appreciation will be to my family especially my beloved parents for their great support, patience, love, encouragement and providing me with the inspiration to pursue my study.

May Allah (s.w.t) bless you all, Amin.

## TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS	ii
TABLE OF CONTENTS	iv
LIST OF TABLES	ix
LIST OF FIGURES	x
LIST OF ABBREVIATION	xii
ABSTRAK	xiv
ABSTRACT	xvi

### CHAPTER ONE: LITERATURE REVIEW

1.1	Introduction to TB	1
1.2	History of TB	3
1.3	<i>Mycobacterium tuberculosis</i>	4
	1.3.1 Cell wall of <i>M. tuberculosis</i>	5
	1.3.2 Genome of <i>M. tuberculosis</i>	8
1.4	Transmission of TB	9
1.5	Pulmonary and extrapulmonary TB	
	1.5.1 Pulmonary TB	10
	1.5.2 Extrapulmonary TB	11
1.6	Symptoms of TB	11
1.7	Immune response to TB	13
	1.7.1 Early host response	15
	1.7.2 Host specific immune mechanisms in TB	
	1.7.2(a) Humoral immune response	18
	1.7.2(b) Cellular immune response	19
1.8	Diagnosis of TB	23
1.9	Treatment and control of TB	25
1.10	BCG vaccine and its efficacy	26
1.11	New vaccine approaches for TB	
	1.11.1 DNA vaccine	28

1.11.1(a) DNA vaccine delivery	29
1.11.1(b) Mechanisms of DNA vaccine stimulation	31
1.11.1(c) Advantages of DNA vaccine	34
1.11.2 Intracellular bacteria as a delivery vehicle & the use of bacteria in surface display system	35
1.11.3 Prime boost vaccination strategy	38
1.12 Objectives of the study	41

## **CHAPTER TWO: MATERIALS AND METHODS**

2.1 Materials	
2.1.1 Mice	44
2.1.2 Bacterial strains	44
2.1.3 Plasmids	44
2.1.4 Chemicals	46
2.1.5 Antibodies and peptides	46
2.1.6 Kits, consumables and laboratory equipment	46
2.1.7 Water and sterilization	46
2.1.8 Media	
2.1.8(a) Luria-Bertani (LB) Broth	58
2.1.8(b) Luria-Bertani (LB) Agar	58
2.1.8(c) Tryptic Soy Broth (TSB)	59
2.1.8(d) Tryptic Soy Agar (TSA)	59
2.1.9 Buffers	
2.1.9(a) Phosphate Buffered Saline (PBS)	60
2.1.9(b) 1X Tris / EDTA (TE) buffer	60
2.1.9(c) 10X Tris-Borate / EDTA (TBE) electrophoresis buffer	60
2.1.9(d) Transformation Storage Buffer (TSB)	61
2.1.9(e) Resolving gel buffer	61
2.1.9(f) Stacking gel buffer	62
2.1.9(g) Running buffer	62
2.1.9(h) Sample buffer for SDS-PAGE	63
2.1.9(i) Tris Buffered Saline (TBS)	63
2.1.9(j) Tris Buffered Saline-Tween (TBST)	64

2.1.9(k) Staining buffer for Western blot	64
2.1.9(l) Bacterial lysis buffer	64
2.1.9(m) Transfer buffer for Western blot	65
2.1.9(n) Skimmed milk (3%)	65
2.1.9(o) RPMI 1640 medium	65
2.1.9(p) ACK lysis buffer (6X) for lysis of erythrocytes	66
2.1.9(q) Staining buffer for Flow cytometry	66
<b>2.1.10. Solutions</b>	
2.1.10(a) Ampicillin stock solution (100 mg/ml)	67
2.1.10(b) Glucose (2 M)	67
2.1.10(c) NaOH (1 N)	67
2.1.10(d) MgCl <sub>2</sub> (10 mM)	68
2.1.10(e) CaCl <sub>2</sub> (100 mM)	68
2.1.10(f) Na <sub>2</sub> -EDTA (0.5 M, pH 8.0)	68
2.1.10(g) Sodium acetate 3H <sub>2</sub> O (3 M)	69
2.1.10(h) Ethidium bromide (10 mg/ml)	69
2.1.10(i) Isopropyl-beta-D-thiogalactopyranoside (IPTG) stock solution, 0.1 M	69
2.1.10(j) Lysozyme solution (10 mg/ml)	69
2.1.10(k) Coomassie brilliant blue protein gel stain	70
2.1.10(l) 5X Coomassie destaining solution	70
2.1.10(m) Staining solution for Western blot	70
2.1.10(n) NaHCO <sub>3</sub> (3%)	71
2.1.10(o) Phenylmethylsulfonyl fluoride (PMSF), 100 mM	71
<b>2.1.11 Restriction enzymes (RE)</b>	<b>71</b>
<b>2.1.12 Molecular weight markers</b>	
2.1.12(a) DNA molecular weight markers	73
2.1.12(b) Low molecular weight marker (SDS-PAGE)	73
2.1.12(c) 6X His protein ladder for Western blot	73
<b>2.2 Methods</b>	
2.2.1 Preparation of Competent Cells by CaCl <sub>2</sub> Method	73

2.2.2	Transformation of plasmid DNA into competent cells by heat-shock method	74
2.2.3	Long term-storage of the transformed bacteria	76
2.2.4	Extraction of Plasmid using QIAprep Spin Miniprep Kit	77
2.2.5	Screening by Restriction Endonuclease (RE) digestion	78
2.2.6	Determination of DNA concentration	79
2.2.7	Purification of Inak-nVacII protein by metal chelate affinity	79
	2.2.7(a) B-PER 6X His Spin Purification Kit (PIERCE)	80
	2.2.7(b) Dialysis of the purified protein	81
	2.2.7(c) Determination of protein concentration	81
2.2.8	Separation of protein by SDS-PAGE	82
2.2.9	The semi-dry Western blot transfer	83
	2.2.9(a) Western Blotting	84
2.2.10	Immunogenicity studies	
	2.2.10(a) Preparation of naked DNA vaccine candidate for immunization	85
	2.2.10(b) Preparation of surface display vaccine candidate for immunization	87
	2.2.10(c) Immunization of mice	88
	2.2.10(d) Collection of blood	91
	2.2.10(e) Collection of spleens	91
	2.2.10(f) Splenocyte preparation	92
	2.2.10(g) Cell culture	93
	2.2.10(h) Determination of total serum IgG against Inak-nVacII	94
	2.2.10(i) Lymphocyte transformation test (LTT)	94
	2.2.10(j) Extracellular cytokine assay by ELISA	95
	2.2.10(k) Intracellular cytokine assay by flow cytometry	96
2.2.11	Statistical analysis	98

## **CHAPTER THREE: RESULTS**

3.1	Preparation of vaccine candidates and their controls for mice vaccination	99
-----	---	----

2.2.2	Transformation of plasmid DNA into competent cells by heat-shock method	74
2.2.3	Long term-storage of the transformed bacteria	76
2.2.4	Extraction of Plasmid using QIAprep Spin Miniprep Kit	77
2.2.5	Screening by Restriction Endonuclease (RE) digestion	78
2.2.6	Determination of DNA concentration	79
2.2.7	Purification of Inak-nVacII protein by metal chelate affinity	79
	2.2.7(a) B-PER 6X His Spin Purification Kit (PIERCE)	80
	2.2.7(b) Dialysis of the purified protein	81
	2.2.7(c) Determination of protein concentration	81
2.2.8	Separation of protein by SDS-PAGE	82
2.2.9	The semi-dry Western blot transfer	83
	2.2.9(a) Western Blotting	84
2.2.10	Immunogenicity studies	
	2.2.10(a) Preparation of naked DNA vaccine candidate for immunization	85
	2.2.10(b) Preparation of surface display vaccine candidate for immunization	87
	2.2.10(c) Immunization of mice	88
	2.2.10(d) Collection of blood	91
	2.2.10(e) Collection of spleens	91
	2.2.10(f) Splenocyte preparation	92
	2.2.10(g) Cell culture	93
	2.2.10(h) Determination of total serum IgG against Inak-nVacII	94
	2.2.10(i) Lymphocyte transformation test (LTT)	94
	2.2.10(j) Extracellular cytokine assay by ELISA	95
	2.2.10(k) Intracellular cytokine assay by flow cytometry	96
2.2.11	Statistical analysis	98

## **CHAPTER THREE: RESULTS**

3.1	Preparation of vaccine candidates and their controls for mice vaccination	99
-----	---	----



3.2	Recombinant Inak-nVacll preparation for immunological assays	100
3.3	Serum IgG Antibody in mice vaccinated with pJWVacll and r-STVacll	105
3.4	Proliferative response of lymphocyte from vaccinated mice	105
3.5	IFN- $\gamma$ secretion of lymphocyte from mice vaccinated with the vaccine candidates	113
3.6	Intracellular cytokine (IFN- $\gamma$ and IL-2) by CD4 <sup>+</sup> and CD8 <sup>+</sup> T-cell from vaccinated mice	119
<b>CHAPTER FOUR: DISCUSSION AND CONCLUSION</b>		125
<b>BIBLIOGRAPHY</b>		138
<b>APPENDICES</b>		148

## LIST OF TABLES

	Page	
1.1	The differences between latent TB infection and active TB disease	14
1.2	Commendable qualities of DNA vaccines	36
2.1	List of bacterial species and strains	45
2.2	List of chemicals and reagents	52
2.3	List of antibodies	54
2.4	List of peptides	55
2.5	List of kits and miscellaneous reagents	56
2.6	List of equipments	57
2.7	Restriction endonuclease (RE) used in this study	72
2.8	Immunization protocol	90
3.1	The ratio of intracellular cytokine (IFN- $\gamma$ ) secretion between test and control animals from Groups A and B respectively	124
3.2	The ratio of intracellular cytokine (IL-2) secretion between test and control animal from Groups A and B respectively	124
4.1	Summary of results of immunogenicity assays of the different vaccination formats	134

## LIST OF FIGURES

	Page	
1.1	Tuberculosis notification rates, as of 22 March 2006.	2
1.2	Schematic representation of the mycobacterial cell wall	6
1.3	Progression of the disease in the lung.	12
1.4	DNA vaccination results in DC maturation and migration	30
1.5	DNA vaccination mimics viral infection	32
1.6	Mechanism of action of plasmid DNA vaccine	33
1.7	Mechanisms of prime-boost vaccination strategies	39
1.8	Flow chart of the study	43
2.1	The map of pJW4303 expression vector for development of DNA vaccine	47
2.2	The map of pKK223-3 expression vector for development of surface display vaccine	48
2.3	The map of pJWVacII plasmid for DNA vaccine development	49
2.4	The map of pKMSInak-nVacII plasmid for surface display vaccine development	50
2.5	Complete sequence of the designed VacII gene with the translated amino acid sequence including the MRGS-6xH tag	51
3.1	Screening of pJW4303 and pJWVacII by restriction endonuclease (RE) double digestion	101
3.2	Screening of pKK223-3 and pKMSInak-nVacII by restriction endonuclease (RE) double digestion	102
3.3	Screening of Inak-nVacII (Inak-VacII-6xHis) protein by SDS-PAGE	103
3.4	Western blot analysis of the Inak-nVacII (Inak-VacII-6xHis) protein expression	104
3.5	Serum IgG antibodies in test mice vaccinated with pJWVacII or/and r-STVacII	106
3.6	Lymphocyte proliferation results of Group A	108
3.7	Lymphocyte proliferation results of Group C	109
3.8	Lymphocyte proliferation results of Group B	110
3.9	Lymphocyte proliferation results of Group D	111
3.10	Stimulation Index (S.I) of splenocytes of test mice vaccinated	

using different immunization protocols	112
3.11 Secretion of extracellular IFN- $\gamma$ into the supernatant for Group A	114
3.12 Secretion of extracellular IFN- $\gamma$ into the supernatant for Group C	115
3.13 Secretion of extracellular IFN- $\gamma$ into the supernatant for Group B	116
3.14 Secretion of extracellular IFN- $\gamma$ into the supernatant for Group D	117
3.15 Absorbance values of extracellular IFN- $\gamma$ secretion in the supernatant of test mice vaccinated through different immunization protocols	118
3.16 Assessment of intracellular cytokine for Group A	120
3.17 Assessment of intracellular cytokine for Group B	122

## LIST OF ABBREVIATIONS

AFB	Acid fast bacillus
$\alpha\beta$	Alpha beta
Ag85	Antigen 85
APCs	Antigen presenting cells
BCG	Bacille Calmette Guerin
CMI	Cell mediated immunity
CFU	Colony forming unit
CTL	Cytotoxic T lymphocyte
ddH <sub>2</sub> O	Deionised distilled water
DTH	Delayed type hypersensitivity
DCs	Dendritic cells
DNA	Deoxyribonucleic acid
ER	Endoplasmic reticulum
$\gamma\delta$	Gamma delta
HIV	Human Immunodeficiency Virus
HLA	Human leukocyte antigen
IFN	Interferon
IL	Interleukin
i.m	Intramuscular
i.p	Intraperitoneal
kDa	kilodalton
LB	Luria-Bertani
MHC	Major histocompatibility complex
mAbs	Monoclonal antibodies
MDR-TB	Multi-drug resistant TB
NAA	Nucleic acid amplification
NK	Natural killer
Nramp	Natural-resistance-associated macrophage protein
O.D	Optical density
PBMC	Peripheral blood mononuclear cell
PCR	Polymerase chain reaction

PPD	Purified protein derivative
rBCG	Recombinant bacilli Calmette Guerin
RNI	Reactive nitrogen intermediates
ROI	Reactive oxygen intermediates
RD	Region of difference
RE	Restriction enzyme
SIV	Simian immunodeficiency virus
SI	Stimulation index
Th	T helper
TAP	Transporter associated protein
TB	Tuberculosis
TLR	Toll-like receptor
TNF	Tumor necrosis factor
UV	Ultraviolet
WHO	World Health Organization

**KAJIAN IMUNOLOGI CALON VAKSIN DNA (pJWVacII) DAN VAKSIN  
'SURFACE DISPLAY' (r-STVacII) YANG MENGEKSPRESKAN GEN  
MULTIEPITOP SINTETIK *MYCOBACTERUM TUBERCULOSIS* DALAM  
STRATEGI 'PRIME BOOST' MENGGUNAKAN MODEL MENCIT.**

**ABSTRAK**

Tuberculosis (TB) pada manusia adalah disebabkan oleh patogen bakteria *Mycobacterium tuberculosis* dan merupakan salah satu penyakit utama di dunia. Satu-satunya vaksin TB yang terdapat pada masa ini ialah strain *M. bovis* yang telah dilemahkan iaitu, Bacille Calmette Guerin (BCG). Bagaimanapun, efikasi perlindungan BCG merangkumi julat 0 ke 80% di tempat kajian yang berlainan. Kesan perlindungan BCG adalah ketara pada kanak-kanak tetapi tidak menunjukkan perlindungan terhadap TB paru-paru di kalangan orang dewasa yang menjadi masalah utama. Vaksin DNA merupakan salah satu cara baru untuk mengawal penyakit berjangkit dan boleh merangsang tindak balas kedua-dua sel humoral dan selular. Hasil kajian lepas, calon vaksin pJWVacII dan r-STVacII telah digunakan dalam kajian ini dengan menggunakan strategi '*prime-boost*'. Vaksin DNA, pJWVacII telah diberikan secara intraotot kepada mencit manakala vaksin '*surface display*' pula telah diberikan secara oral kepada mencit. Splenosit dari mencit yang diimunisasi telah diuji dengan pelbagai ujian keimunan. Keputusan menunjukkan bahawa splenosit dari mencit yang diimunisasi memberikan peningkatan gerak balas proliferasi apabila dirangsang dengan antigen (Inak-nVacII). Analisis sitokin intrasel ke atas splenosit juga menunjukkan kedua-dua CD4<sup>+</sup> dan CD8<sup>+</sup> sel T menghasilkan IL-2 dan IFN- $\gamma$  berikutan rangsangan antigen. Dalam kaedah '*prime-boost*', kajian menunjukkan kaedah '*prime*' dengan pJWVacII dan '*boost*'

dengan r-STVaciI adalah strategi terbaik untuk merangsang respon keimunan dalam mencit. Sebagai kesimpulan, data yang diperolehi dari kajian ini mencadangkan bahawa vaksin DNA digabungkan dengan vaksin 'surface display' menggunakan kaedah '*prime-boost*' merupakan salah satu strategi baru untuk membangunkan calon vaksin terhadap TB.



# **IMMUNOLOGICAL STUDIES OF DNA (pJWVacII) AND SURFACE DISPLAY (r-STVacII) VACCINE CANDIDATES EXPRESSING A SYNTHETIC MULTIEPITOPE GENE OF *MYCOBACTERIUM TUBERCULOSIS* IN A PRIME BOOST STRATEGY USING A MOUSE MODEL**

## **ABSTRACT**

Tuberculosis (TB) in humans is caused by the bacterial pathogen *Mycobacterium tuberculosis* and is still a major health problem worldwide. The only TB vaccine currently available is an attenuated strain of *M. bovis*; Bacille Calmette Guerin (BCG). BCG demonstrated variable protective efficacies ranging from 0 to 80% in different field trials. BCG is effective at preventing childhood manifestation of TB but it does not prevent the most prevalent disease which is pulmonary TB in adults. DNA vaccination is an important new approach to the control of infectious agents and induces both humoral and cellular immune responses. Two previously constructed vaccine candidates, pJWVacII and r-STVacII were used in this study employing a prime-boost strategy. The naked DNA vaccine, pJWVacII was given intramuscularly to mice whilst the surface display vaccine, r-STVacII was given orally. Splenocytes from the vaccinated mice were tested for various immunological tests. The results showed that splenocytes from immunized mice were found to proliferate more aggressively when stimulated with the antigen (Inak-nVacII). Flow cytometric intracellular cytokine analysis of splenocytes from vaccinated mice also showed that both CD4<sup>+</sup> and CD8<sup>+</sup> T cells produce IL-2 and IFN- $\gamma$  following stimulation with the antigens. In the prime-boost approach, the study showed that mice primed with the naked DNA vaccine, pJWVacII and boosted with the surface

display vaccine, r-STVacII is the best strategy to stimulate immune response in mice. As a conclusion, the data obtained from this study suggest that DNA vaccination in combination with surface display vaccination using prime-boost approach provides a new strategy for developing a candidate vaccine against TB.

# CHAPTER 1

## INTRODUCTION

### 1.1 Introduction to TB

Tuberculosis (TB) is a contagious and potentially fatal disease that can affect almost any part of the body but manifests mainly as an infection of the lungs. It is caused by a bacterial microorganism, the tubercle bacillus or *Mycobacterium tuberculosis*. TB infection can either be acute and short-lived or chronic and long-term. Approximately 1.7 billion people or one-third of the world's population are infected with the predominant TB organism, *M. tuberculosis*. Currently, 10 to 15 million people in the United States have latent TB infection, and 10 percent of them will develop active disease at some point in their lives (Diana, 2000).

Most people infected with *M. tuberculosis* never develop active TB. However, in people with weakened immune systems, especially those infected with the human immunodeficiency virus (HIV), TB organisms may overcome the body's defenses, multiply, and cause active disease (Ellner, 1990). Each year, 8 million people worldwide develop active TB and 3 million die. TB is often one of the first secondary infections to be activated in HIV – positive individuals. Moreover, poverty, malnutrition and their contributing factors such as political disorganization and war also contribute to the increase rate of TB. Figure 1.1 shows TB notification rate around the world.




Figure 1.1: Tuberculosis notification rates, as of 22 March 2006 (Source: WHO Stop TB Department, website: [www.who.int/tb](http://www.who.int/tb))

## 1.2 History of TB

In the second half of the 17th century, when TB caused high levels of death rates in Europe, John Bunyan gave the title 'captain of all these men of death' for TB, which was also known as the white plaque. Pulmonary TB was known since the time of Hippocrates as phthisis, derived from the Greek for 'wasting away'. In 1680, the French, Franciscus Sylvius carried out anatomic-pathologic studies in pulmonary nodules from TB patients, which he named as 'tubercula' (small knots). These knots were believed to be only some type of tumor or abnormal gland. In 1722, a British doctor Benjamin Marten proposed that TB could be transmitted through the 'breath' of a sick person (reviewed by Rodrigo *et al.*, 2006).

In 1882, Robert Koch isolated and cultured *M. tuberculosis* from crushed tubercles and identified the bacterium as the TB etiological agent. In 1896, an American bacteriologist demonstrated that bovine TB was not caused by *M. tuberculosis* but by a closely related bacterium, *M. bovis*. Twelve years later, Albert Calmette and Camille Guerin isolated the bovine variant from its host and grew the bacilli in dispersed culture containing ox bile. After 13 years of experimentation, the variant was administered for the first time in humans orally, as an attempt to immunize a child whose mother died in childbirth as a victim of TB.

However, WHO indicated that there have not been great effects on the global problem since the time of Koch (Bloom & Murray, 1992). Currently, TB causes

more human deaths than any other single infectious agent, standing for 26% of all preventable deaths and 7% of all deaths (reviewed by Rodrigo *et al.*, 2006).

### **1.3 *Mycobacterium tuberculosis***

The TB bacterium is a rod-shaped bacterium, non-motile, non-spore forming, 1-4  $\mu\text{m}$  in length, and between 0.3-0.6  $\mu\text{m}$  in diameter, making them smaller than most bacterial pathogens (Iseman, 2000 and Akemi *et al.*, 2003). This bacterium belongs to the family Mycobacteriaceae and the order Actinomycetales. *M. tuberculosis*, like other mycobacteria, has an unusual cell wall, a waxy coat comprised of fatty molecules whose structure and function are not well known. This cell wall appears to allow *M. tuberculosis* to survive in its preferred environment: inside immune cells called macrophages, which ordinarily degrade pathogens with enzymes. The coat of *M. tuberculosis* also renders it impermeable to many common drugs.

*M. tuberculosis* and other mycobacteria are also called as “acid fast” bacteria (AFB) which means that they retain certain dyes following an acid-alcohol decolorization step and this characteristic is related to the complex cell wall structure that contains derivatives of mycolic acid (Floyd *et al.*, 1992). In the most common staining technique, Ziehl-Neelsen stain, AFB is stained a bright red which stands out clearly against a blue background. It can also be visualized by fluorescent microscopy and by auramine-rhodamine stain (Batzing, 2002).

There are several factors that contribute to the difficulty in the study of *M. tuberculosis* in the laboratory. First, the bacteria multiply very slowly, only once every 24 hours and take a month to form a colony. Two media are often used to grow *M. tuberculosis*; Middlebrook's medium which is an agar based medium and Lowenstein-Jensen medium which is an egg based medium (American Thoracic Society, 2000).

In comparison, other organism such as *E. coli* form colonies within eight hours. Moreover, TB bacilli tend to form clumps which are difficult to work with or to count the cells. Most daunting, *M. tuberculosis* is a dangerous, airborne organism that can be studied only in laboratories that have specialized safety equipment.

Several species of mycobacteria with similar growth characteristics and biochemical reactions are classified together as the *M. tuberculosis* complex (Cole, 2002). This complex includes *M. bovis*, *M. africanum* and *M. microti* which can also cause TB in mammals. The first two are very rare causes of disease and the last one do not cause human disease (Brosch *et al.*, 2000).

### **1.3.1 The cell wall of *M. tuberculosis***

Mycobacteria produce an extremely uncommon cell wall structure. It is composed of a multilayered cell envelope which basically consists of (from inside the cells to the outer surface): a plasma membrane and three covalently associated macromolecules such as peptidoglycan, arabinogalactan and mycolic acid or glycolipids (Figure 1.2). The plasma membrane is composed of




Figure 1.2: Schematic representation of the mycobacterial cell wall (Adapted from Rodrigo *et al.*, 2006)